The Discovery of a Potent, Selective, and ... - ACS Publications


Oct 21, 2016 - Trk Inhibitor (PF-06273340) for the Treatment of Pain. Sarah E. Skerratt,*,† ... pathogenesis of inflammatory pain,1 with neutralizin...
0 downloads 0 Views 7MB Size

Recommend Documents


Oct 12, 2012 - *Phone: 650-467-6671. E-mail: .... Jung Min Joo. Bulletin of the Korean Chemical Society 2014 35, 3009-3014 ..... ACS Publications regularly produces Virtual Collections of the most important research topics in chemistry .

Oct 21, 2016 - Pfizer Global Research & Development, The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K.. ‡ ... This is an open access article published under an ACS AuthorChoice License, which permits copying and redistrib

Julie M. Bailis , Marcia L. Gordon , Jesse L. Gurgel , Alexis C. Komor ... R de Leeuw , M J Schiewer , W F Ostrander , R A Burkhart , A K McClendon , P A McCue ..... Nicole Sgambellone , Frances Shanahan , Derek Wiswell , Timothy J. Guzi.

Yogesh A. Sonawane , Margaret A. Taylor , John Victor Napoleon , Sandeep Rana , Jacob I. Contreras , and Amarnath Natarajan ..... Huang, Steven K. Wetter, Yanhua Lu, William V. Murray, Stuart L. Emanuel, Robert H. Gruninger, Angel R. Fuentes-Pesquera

Chiao-En Wu , Arman Esfandiari , Yi-Hsuan Ho , Nan Wang , Ahmed Khairallah ..... Doris Phelps , Kathryn Bondra , Star Seum , Christopher Chronowski , Justin ...

Jun 23, 2018 - Asthma is a common chronic lung disease that inflames and narrows the airways and affects millions of people of all ages in all parts of the ...

Mar 25, 2010 - As shown in Table 1, 1 [human norepinephrine transporter (hNET), IC50 = 82 nM] was found to be efficacious when dosed intraperitoneally (ip) ...

Mar 25, 2010 - As shown in Table 1, 1 [human norepinephrine transporter (hNET), IC50 = 82 nM] was found to be efficacious when dosed intraperitoneally (ip) ...

Jun 28, 2013 - Restoration of p53 activity by inhibition of the p53–MDM2 interaction has been considered an attractive approach for cancer treatment. However, the hydrophobic protein–protein interaction surface represents a significant challenge

pharmacodynamic (PD) profiles in pre-clinical and Phase 2 studies are ongoing in patients with rheumatoid arthritis, lupus and ..... In each case whole blood potency improved without any negative impact on other properties. ...... D.L.M.: Alios BioPh